Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Moderna shares dropped nearly 5% on Wednesday after Citi downgraded its rating to Sell from Neutral, citing valuation concerns following a recent rally. The firm also raised its price target to $80 from $60.
The S&P 500, Nasdaq and Dow rose after the Commerce Department said August PCE increased 3.4% year on year, below expectations. Traders cut bets on an October rate hike, while Boeing, Moderna and HPE moved on company-specific news.
Moderna shares fell 6.2% to $190.89 premarket after Citigroup downgraded MRNA to "sell" from "neutral"; Citi raised its price target to $80 from $60.